Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Myriad Genetics Inc (NQ: MYGN)
28.62 USD  -0.17 (-0.59%)
Official Closing Price  /  Updated: 4:41 PM EST, Jan 24, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 609,500
Open 28.87
Bid (Size) 28.59 (1)
Ask (Size) 30.00 (3)
Prev. Close 28.79
Today's Range 28.35 - 28.93
52wk Range 20.10 - 48.40
Shares Outstanding 69,906,818
Dividend Yield N/A
Performance
YTD
+4.64%
+4.64%
1 Month
+6.55%
+6.55%
3 Month
-14.26%
-14.26%
6 Month
-0.31%
-0.31%
1 Year
+3.32%
+3.32%
Top News
More News
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
from GlobeNewswire News Releases
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
from GlobeNewswire News Releases
More News
Read More
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
from GlobeNewswire News Releases
Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference
from GlobeNewswire News Releases
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
from GlobeNewswire News Releases
Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert
from Business Wire News Releases
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
from GlobeNewswire News Releases
PRESS DIGEST -Wall Street Journal - Jan 13
category companyNews
from Reuters: Company News
Myriad Genetics Shares Cross Above 200 DMA
category Stocks
from Market News Video
This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval
from Investor's Business Daily
INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.